Avacta Therapeutics Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
75
- Stock Symbol
-
AVCT
- Investments
-
9
- Share Price
-
$0.82
- (As of Thursday Closing)
Avacta Therapeutics General Information
Description
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
Contact Information
Website
avacta.comCorporate Office
- Scale Space, White City
- Imperial College Campus, 58 Wood Lane
- London W12 7RZ
- England, United Kingdom
Corporate Office
- Scale Space, White City
- Imperial College Campus, 58 Wood Lane
- London W12 7RZ
- England, United Kingdom
Avacta Therapeutics Timeline
Avacta Therapeutics Stock Performance
As of 12-Nov-2026, Avacta Therapeutics’s stock price is $0.82. Its current market cap is $358M with 438M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.82 | $0.80 | $0.66 - $1.25 | $358M | 438M | 1.95M | -$0.12 |
Avacta Therapeutics Financials Summary
As of 30-Jun-2026, Avacta Therapeutics has a trailing 12-month revenue of $152K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 453,840 | 348,778 | 216,819 | 411,647 |
| Revenue | 152 | 149 | 144 | 3,544 |
| EBITDA | (41,276) | (37,018) | (20,984) | (16,340) |
| Net Income | (53,548) | (50,860) | (67,516) | (41,339) |
| Total Assets | 41,006 | 39,612 | 60,568 | 93,238 |
| Total Debt | 21,965 | 20,087 | 28,778 | 40,155 |
Avacta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Avacta Therapeutics Comparisons
Industry
Financing
Details
Avacta Therapeutics Competitors (3)
One of Avacta Therapeutics’s 3 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Phaxiam | Formerly VC-backed | Lyon, France | ||||
| Quell Therapeutics | Venture Capital-Backed | London, United Kingdom |
Avacta Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Avacta Therapeutics Patents
Avacta Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026074156-A1 | Fap-activated camptothecin conjugates and uses thereof | Pending | 04-Oct-2024 | ||
| WO-2026002988-A1 | Fibroblast activation protein alpha binder proteins | Pending | 24-Jun-2024 | ||
| WO-2026002995-A1 | Target-specific fap-activated topoisomerase inhibitor conjugates and uses thereof | Pending | 24-Jun-2024 | ||
| GB-202403780-D0 | Polypeptides and methods for detecting and quantifying small molecules | Inactive | 15-Mar-2024 | ||
| WO-2025191078-A1 | Polypeptides and methods for detecting and quantifying small molecules | Pending | 15-Mar-2024 | G01N33/82 |
Avacta Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avacta Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Avacta Therapeutics Investments & Acquisitions (9)
Avacta Therapeutics’s most recent deal was a Merger/Acquisition with Coris BioConcept for . The deal was made on 01-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Coris BioConcept | 01-Jun-2023 | Merger/Acquisition | Medical Supplies | ||
| Launch Diagnostics | 21-Oct-2022 | Merger/Acquisition | Distributors (Healthcare) | ||
| AffyXell Therapeutics | 08-Jan-2020 | Joint Venture | Drug Discovery | ||
| Aptuscan | 09-Jan-2012 | Merger/Acquisition | Biotechnology | ||
| Reactivlab | 03-Mar-2010 | Merger/Acquisition | Other Commercial Services |
Avacta Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.14 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Avacta Therapeutics Exits (3)
Avacta Therapeutics’s most recent exit was on 01-Jun-2023 from Coris BioConcept. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Coris BioConcept | 01-Jun-2023 | Completed |
|
||
| Launch Diagnostics | 21-Oct-2022 | Completed |
|
||
| YorkTest Laboratories | 09-Feb-2009 | Merger/Acquisition | Completed |
Avacta Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aptuscan | Leeds, United Kingdom | 2008 | |
| Avacta Analytical | Wetherby, United Kingdom | 2004 |
Avacta Therapeutics FAQs
-
When was Avacta Therapeutics founded?
Avacta Therapeutics was founded in 2003.
-
Where is Avacta Therapeutics headquartered?
Avacta Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Avacta Therapeutics?
Avacta Therapeutics has 75 total employees.
-
What industry is Avacta Therapeutics in?
Avacta Therapeutics’s primary industry is Biotechnology.
-
Is Avacta Therapeutics a private or public company?
Avacta Therapeutics is a Public company.
-
What is Avacta Therapeutics’s stock symbol?
The ticker symbol for Avacta Therapeutics is AVCT.
-
What is the current stock price of Avacta Therapeutics?
As of 12-Nov-2026 the stock price of Avacta Therapeutics is $0.82.
-
What is the current market cap of Avacta Therapeutics?
The current market capitalization of Avacta Therapeutics is $358M.
-
What is Avacta Therapeutics’s current revenue?
The trailing twelve month revenue for Avacta Therapeutics is $152K.
-
Who are Avacta Therapeutics’s competitors?
Autolus, Phaxiam, and Quell Therapeutics are competitors of Avacta Therapeutics.
-
What is Avacta Therapeutics’s annual earnings per share (EPS)?
Avacta Therapeutics’s EPS for 12 months was -$0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
